Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Decreases By 21.1%

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 126,900 shares, a decrease of 21.1% from the December 15th total of 160,800 shares. Based on an average daily trading volume, of 2,280,000 shares, the short-interest ratio is currently 0.1 days. Currently, 7.6% of the shares of the stock are short sold.

180 Life Sciences Stock Performance

Shares of NASDAQ ATNF traded down $0.02 during trading hours on Friday, hitting $1.56. 85,595 shares of the stock were exchanged, compared to its average volume of 1,006,117. 180 Life Sciences has a 1-year low of $1.16 and a 1-year high of $17.75. The company’s fifty day simple moving average is $2.10 and its two-hundred day simple moving average is $2.23.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.